Last reviewed · How we verify
Humulin-N
Humulin-N is an intermediate-acting insulin that lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism.
Humulin-N is an intermediate-acting insulin that lowers blood glucose by facilitating cellular glucose uptake and promoting anabolic metabolism. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Humulin-N |
|---|---|
| Also known as | NPH insulin |
| Sponsor | Taipei Veterans General Hospital, Taiwan |
| Drug class | Intermediate-acting insulin |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Humulin-N (NPH insulin) is a recombinant human insulin suspension with protamine, which slows insulin absorption and extends its duration of action to 10-16 hours. It binds to insulin receptors on muscle, fat, and liver cells, promoting glucose uptake and storage while inhibiting hepatic glucose production. This mimics the endogenous basal insulin secretion pattern in non-diabetic individuals.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Injection site reactions
- Lipodystrophy
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Surgical or Medical Treatment (PHASE4)
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (PHASE2)
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
- Avexitide for Treatment of Post-Bariatric Hypoglycemia (PHASE3)
- Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation (NA)
- Efficacy of Chromium Picolinate in Reducing Acanthosis Nigricans Severity in Adolescents With Insulin Resistance (NA)
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Humulin-N CI brief — competitive landscape report
- Humulin-N updates RSS · CI watch RSS
- Taipei Veterans General Hospital, Taiwan portfolio CI